Aug. 29, 2013, 4:09 PM
- Opko Health (OPK -1%) says it's completed its acquisition of Prolor Biotech (PBTH).
- Under the terms of the deal, each PBTH stockholder will receive 0.9951 shares of OPK.
- The acquisition provides OPK with four significant products in Phase III clinical development, as well as a pipeline of important therapeutic and unique diagnostic products in various stages of development.
Apr. 24, 2013, 9:08 AM
Prolor Biotech (PBTH), will be acquired by OPKO Health (OPK) in an all-stock deal worth $480M. PBTH shareholders will get 0.9551 shares of OPK for every share of PBTH they own, equating to $7 per share as of Tuesday's closing prices. PBTH +10.65% premarket. (Previously: strategic alternative evaluation boosts Prolor)| Apr. 24, 2013, 9:08 AM | 2 Comments